Third Harmonic Bio, Inc. (THRD)

Market Cap	156.35M
Revenue (ttm)	n/a
Net Income (ttm)	-39.20M
Shares Out	45.06M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	509,780
Open	3.600
Previous Close	3.580
Day's Range	3.465 - 3.670
52-Week Range	3.180 - 16.940
Beta	2.67
Analysts	Buy
Price Target	14.00 (+303.46%)
Earnings Date	Mar 25, 2025

About THRD

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2022
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: THRD
• Website: https://www.thirdharmonicbio.com

Analyst Forecast

According to 3 analysts, the average rating for THRD stock is "Buy." The 12-month stock price forecast is $14.0, which is an increase of 303.46% from the latest price.

Price Target

$14.0

(303.46% upside)

Analyst Consensus: Buy